We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Institute for Systems Biology Completes Purchase of Cyntellect LEAP™ System
News

Institute for Systems Biology Completes Purchase of Cyntellect LEAP™ System

Institute for Systems Biology Completes Purchase of Cyntellect LEAP™ System
News

Institute for Systems Biology Completes Purchase of Cyntellect LEAP™ System

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Institute for Systems Biology Completes Purchase of Cyntellect LEAP™ System"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cyntellect, Inc. has announced that the Institute for Systems Biology (ISB) has completed the purchase and installation of Cyntellect's Laser- Enabled Analysis and Processing (LEAP) system in its Seattle, Washington facility. ISB plans to exploit LEAP's in situ live cell manipulation capabilities to enable new approaches to functionally cloning immune cells and determining their potential roles in mediating disease.

"LEAP is an exciting new technology that will facilitate many different aspects of systems approaches to disease" stated Dr. Leroy Hood, President of ISB.

LEAP is an automated live-cell manipulation system that combines high- speed optical imaging of cells (brightfield or fluorescence), real-time image analysis with high-speed in situ laser manipulation of live cells.

Using LEAP, researchers have demonstrated: (i) accelerated functional cloning of cells, including highly-secreting cells for biopharmaceutical manufacturing purposes, (ii) image-based cell purification of adherent and non-adherent cell types and (iii) laser-based macro molecule delivery, including siRNA, small molecules, proteins and quantum dots.

"ISB is an institute well-known for performing high-quality research to define, understand and resolve the mechanisms of cellular diseases," stated Dr. Fred Koller, Cyntellect's President and CEO. "ISB's appreciation for the unique role LEAP can play in this process is testimony to the potential for in situ live-cell processing and we are proud to have ISB as a customer."

ISB's LEAP purchase was supported in part through grant S10 RR023639-01, awarded to ISB by the NIH's National Center for Research Resources under their Shared Instrumentation Grant Program.

Advertisement